<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 20, 1999
PHARMERICA, INC.
(Exact name of Registrant as specified in its charter)
Delaware 0-20606 11-2310352
- ---------------------------- ------------------------ ----------------------
(State or other jurisdiction (Commission file Number) (Employer
of incorporation) Identification Number)
175 Kelsey Lane, Tampa, Florida 33619
- --------------------------------------------------------------------------------
(Address of principal executive offices)
(813) 626-7788
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER EVENTS.
On April 20, 1999, PharMerica, Inc. and Bergen Brunswig Corporation
announced that in a hearing on April 20 in the Superior Court of California,
San Diego County, PharMerica and Bergen were allowed to continue the merger
transaction.
On April 14, Bergen and PharMerica were named as defendants in a
lawsuit commenced by PMR Corp., seeking, among other things, injunctive relief
preventing Bergen from closing its proposed acquisition of PharMerica.
On April 20, Judge S. Charles Wickersham denied PMR's request for a
temporary restraining order. Shareowners of Bergen and PharMerica will vote
April 22, 1999, as scheduled, on approval of the pending merger.
Statements in this press release regarding future events constitute
forward-looking statements under the Private Securities Litigation Reform Act
of 1995. Forward-looking statements contained in this press release are subject
to certain risks and uncertainties that could cause actual results to differ
materially from those implied by such forward-looking statements. Because of
the uncertainty of all litigation, there can be no assurance that Bergen and
PharMerica will be successful defending against the underlying claims in PMR's
lawsuit. Certain additional risks associated with PharMerica and Bergen are set
forth in reports that they have filed with the Securities and Exchange
Commission, including Bergen's Annual Report on Form 10-K for the year ended
September 30, 1998 and PharMerica's Annual Report on Form 10-K for the year
ended December 31, 1998.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMERICA, INC.
By: /s/ David Redmond
---------------------------------------
David Redmond
Executive Vice President and Chief
Financial Officer
Date: April 21, 1999
3
